Exact Mass: 729.5308266

PC(14:0/18:2(9Z,12Z))

C40H76NO8P (729.5308266)

PC(14:0/18:2(9Z,12Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(14:0/18:2(9Z,12Z)), in particular, consists of one chain of myristic acid at the C-1 position and one chain of linoleic acid at the C-2 position. The myristic acid moiety is derived from nutmeg and butter, while the linoleic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC.

PC(16:1(9Z)/16:1(9Z))

C40H76NO8P (729.5308266)

PC(16:1(9Z)/16:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(16:1(9Z)/16:1(9Z)), in particular, consists of two chains of palmitoleic acid at the C-1 and C-2 positions. The palmitoleic acid moieties are derived from animal fats and vegetable oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. PC(16:1(9Z)/16:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(16:1(9Z)/16:1(9Z)), in particular, consists of two chains of palmitoleic acid at the C-1 and C-2 positions. The palmitoleic acid moieties are derived from animal fats and vegetable oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PC(14:1(9Z)/18:1(11Z))

C40H76NO8P (729.5308266)

PC(14:1(9Z)/18:1(11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(14:1(9Z)/18:1(11Z)), in particular, consists of one chain of myristoleic acid at the C-1 position and one chain of vaccenic acid at the C-2 position. The myristoleic acid moiety is derived from milk fats, while the vaccenic acid moiety is derived from butter fat and animal fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC.

PC(14:1(9Z)/18:1(9Z))

C40H76NO8P (729.5308266)

PC(14:1(9Z)/18:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(14:1(9Z)/18:1(9Z)), in particular, consists of one chain of myristoleic acid at the C-1 position and one chain of oleic acid at the C-2 position. The myristoleic acid moiety is derived from milk fats, while the oleic acid moiety is derived from vegetable oils, especially olive and canola oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC.

PC(15:0/P-18:1(11Z))

C41H80NO7P (729.5672099999999)

PC(15:0/P-18:1(11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(15:0/P-18:1(11Z)), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The pentadecanoic acid moiety is derived from dairy products and milk fat, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

PC(15:0/P-18:1(9Z))

C41H80NO7P (729.5672099999999)

PC(15:0/P-18:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(15:0/P-18:1(9Z)), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The pentadecanoic acid moiety is derived from dairy products and milk fat, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(15:0/P-18:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(15:0/P-18:1(9Z)), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The pentadecanoic acid moiety is derived from dairy products and milk fat, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PC(18:1(11Z)/14:1(9Z))

C40H76NO8P (729.5308266)

PC(18:1(11Z)/14:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(18:1(11Z)/14:1(9Z)), in particular, consists of one chain of vaccenic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. The vaccenic acid moiety is derived from butter fat and animal fat, while the myristoleic acid moiety is derived from milk fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. PC(18:1(11Z)/14:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(18:1(11Z)/14:1(9Z)), in particular, consists of one chain of vaccenic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. The vaccenic acid moiety is derived from butter fat and animal fat, while the myristoleic acid moiety is derived from milk fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PC(18:1(9Z)/14:1(9Z))

C40H76NO8P (729.5308266)

PC(18:1(9Z)/14:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(18:1(9Z)/14:1(9Z)), in particular, consists of one chain of oleic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. The oleic acid moiety is derived from vegetable oils, especially olive and canola oil, while the myristoleic acid moiety is derived from milk fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC.

PC(18:2(9Z,12Z)/14:0)

C40H76NO8P (729.5308266)

PC(18:2(9Z,12Z)/14:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(18:2(9Z,12Z)/14:0), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of myristic acid at the C-2 position. The linoleic acid moiety is derived from seed oils, while the myristic acid moiety is derived from nutmeg and butter. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC.

PE(15:0/20:2(11Z,14Z))

C40H76NO8P (729.5308266)

PE(15:0/20:2(11Z,14Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(15:0/20:2(11Z,14Z)), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of eicosadienoic acid at the C-2 position. The pentadecanoic acid moiety is derived from dairy products and milk fat, while the eicosadienoic acid moiety is derived from fish oils and liver. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS.

PE(18:0/P-18:1(11Z))

C41H80NO7P (729.5672099999999)

PE(18:0/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:0/P-18:1(11Z)), in particular, consists of one chain of stearic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The stearic acid moiety is derived from animal fats, coco butter and sesame oil, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

PE(18:0/P-18:1(9Z))

C41H80NO7P (729.5672099999999)

PE(18:0/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:0/P-18:1(9Z)), in particular, consists of one chain of stearic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The stearic acid moiety is derived from animal fats, coco butter and sesame oil, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

PE(18:1(11Z)/P-18:0)

C41H80NO7P (729.5672099999999)

PE(18:1(11Z)/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:1(11Z)/P-18:0), in particular, consists of one chain of vaccenic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The vaccenic acid moiety is derived from butter fat and animal fat, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

PE(18:1(9Z)/P-18:0)

C41H80NO7P (729.5672099999999)

PE(18:1(9Z)/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:1(9Z)/P-18:0), in particular, consists of one chain of oleic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The oleic acid moiety is derived from vegetable oils, especially olive and canola oil, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

PE(20:1(11Z)/P-16:0)

C41H80NO7P (729.5672099999999)

PE(20:1(11Z)/P-16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:1(11Z)/P-16:0), in particular, consists of one chain of eicosenoic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The eicosenoic acid moiety is derived from vegetable oils and cod oils, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

PE(20:2(11Z,14Z)/15:0)

C40H76NO8P (729.5308266)

PE(20:2(11Z,14Z)/15:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:2(11Z,14Z)/15:0), in particular, consists of one chain of eicosadienoic acid at the C-1 position and one chain of pentadecanoic acid at the C-2 position. The eicosadienoic acid moiety is derived from fish oils and liver, while the pentadecanoic acid moiety is derived from dairy products and milk fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS.

PC(P-18:1(11Z)/15:0)

C41H80NO7P (729.5672099999999)

PC(P-18:1(11Z)/15:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(11Z)/15:0), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of pentadecanoic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the pentadecanoic acid moiety is derived from dairy products and milk fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

PC(P-18:1(9Z)/15:0)

C41H80NO7P (729.5672099999999)

PC(P-18:1(9Z)/15:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(9Z)/15:0), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of pentadecanoic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the pentadecanoic acid moiety is derived from dairy products and milk fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-18:1(9Z)/15:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(9Z)/15:0), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of pentadecanoic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the pentadecanoic acid moiety is derived from dairy products and milk fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(P-16:0/20:1(11Z))

C41H80NO7P (729.5672099999999)

PE(P-16:0/20:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/20:1(11Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of eicosenoic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the eicosenoic acid moiety is derived from vegetable oils and cod oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

PE(P-18:0/18:1(11Z))

C41H80NO7P (729.5672099999999)

PE(P-18:0/18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/18:1(11Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of vaccenic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the vaccenic acid moiety is derived from butter fat and animal fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS.Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(dm18:0/18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(dm18:0/18:1(11Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of vaccenic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the vaccenic acid moiety is derived from butter fat and animal fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(P-18:0/18:1(9Z))

C41H80NO7P (729.5672099999999)

PE(P-18:0/18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/18:1(9Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of oleic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the oleic acid moiety is derived from vegetable oils, especially olive and canola oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:0/18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/18:1(9Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of oleic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the oleic acid moiety is derived from vegetable oils, especially olive and canola oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE-NMe(14:1(9Z)/20:1(11Z))

C40H76NO8P (729.5308266)

PE-NMe(14:1(9Z)/20:1(11Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(14:1(9Z)/20:1(11Z)), in particular, consists of one 9Z-tetradecenoyl chain to the C-1 atom, and one 11Z-eicosenoyl to the C-2 atom. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE-NMe(16:1(9Z)/18:1(9Z))

C40H76NO8P (729.5308266)

PE-NMe(16:1(9Z)/18:1(9Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(16:1(9Z)/18:1(9Z)), in particular, consists of one 9Z-hexadecenoyl chain to the C-1 atom, and one 9Z-octadecenoyl to the C-2 atom. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE-NMe(16:1(9Z)/18:1(11Z))

C40H76NO8P (729.5308266)

PE-NMe(16:1(9Z)/18:1(11Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(16:1(9Z)/18:1(11Z)), in particular, consists of one 9Z-hexadecenoyl chain to the C-1 atom, and one 11Z-octadecenoyl to the C-2 atom. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE-NMe(14:0/20:2(11Z,14Z))

C40H76NO8P (729.5308266)

PE-NMe(14:0/20:2(11Z,14Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(14:0/20:2(11Z,14Z)), in particular, consists of one chain of myristic acid at the C-1 position and one chain of eicosadienoic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.

PE-NMe(16:0/18:2(9Z,12Z))

C40H76NO8P (729.5308266)

PE-NMe(16:0/18:2(9Z,12Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(16:0/18:2(9Z,12Z)), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of linoleic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.

PE-NMe(18:1(11Z)/16:1(9Z))

C40H76NO8P (729.5308266)

PE-NMe(18:1(11Z)/16:1(9Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(18:1(11Z)/16:1(9Z)), in particular, consists of one chain of cis-vaccenic acid at the C-1 position and one chain of palmitoleic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.

PE-NMe(18:1(9Z)/16:1(9Z))

C40H76NO8P (729.5308266)

PE-NMe(18:1(9Z)/16:1(9Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(18:1(9Z)/16:1(9Z)), in particular, consists of one chain of oleic acid at the C-1 position and one chain of palmitoleic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.

PE-NMe(18:2(9Z,12Z)/16:0)

C40H76NO8P (729.5308266)

PE-NMe(18:2(9Z,12Z)/16:0) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(18:2(9Z,12Z)/16:0), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of palmitic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.

PE-NMe(20:1(11Z)/14:1(9Z))

C40H76NO8P (729.5308266)

PE-NMe(20:1(11Z)/14:1(9Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(20:1(11Z)/14:1(9Z)), in particular, consists of one chain of eicosenoic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.

PE-NMe(20:2(11Z,14Z)/14:0)

C40H76NO8P (729.5308266)

PE-NMe(20:2(11Z,14Z)/14:0) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(20:2(11Z,14Z)/14:0), in particular, consists of one chain of eicosadienoic acid at the C-1 position and one chain of myristic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.

PE-NMe2(15:0/18:2(9Z,12Z))

C40H76NO8P (729.5308266)

PE-NMe2(15:0/18:2(9Z,12Z)) is a dimethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Dimethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe2(15:0/18:2(9Z,12Z)), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of linoleic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.

PE-NMe2(18:2(9Z,12Z)/15:0)

C40H76NO8P (729.5308266)

PE-NMe2(18:2(9Z,12Z)/15:0) is a dimethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Dimethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe2(18:2(9Z,12Z)/15:0), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of pentadecanoic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.

Ibrexafungerp

C44H67N5O4 (729.5192781999999)

PE(14:0/20:3(6,8,11)-OH(5))

C39H72NO9P (729.4944432)

PE(14:0/20:3(6,8,11)-OH(5)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(14:0/20:3(6,8,11)-OH(5)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 5-hydroxyeicosatetrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

PE(20:3(6,8,11)-OH(5)/14:0)

C39H72NO9P (729.4944432)

PE(20:3(6,8,11)-OH(5)/14:0) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(20:3(6,8,11)-OH(5)/14:0), in particular, consists of one chain of one 5-hydroxyeicosatetrienoyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

PE(16:0/18:2(10E,12Z)+=O(9))

C39H72NO9P (729.4944432)

PE(16:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(16:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one hexadecanoyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

PE(18:2(10E,12Z)+=O(9)/16:0)

C39H72NO9P (729.4944432)

PE(18:2(10E,12Z)+=O(9)/16:0) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(18:2(10E,12Z)+=O(9)/16:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of hexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

PE(16:0/18:2(9Z,11E)+=O(13))

C39H72NO9P (729.4944432)

PE(16:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(16:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one hexadecanoyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

PE(18:2(9Z,11E)+=O(13)/16:0)

C39H72NO9P (729.4944432)

PE(18:2(9Z,11E)+=O(13)/16:0) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(18:2(9Z,11E)+=O(13)/16:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of hexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

PE(16:0/18:3(10,12,15)-OH(9))

C39H72NO9P (729.4944432)

PE(16:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(16:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one hexadecanoyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

PE(18:3(10,12,15)-OH(9)/16:0)

C39H72NO9P (729.4944432)

PE(18:3(10,12,15)-OH(9)/16:0) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(18:3(10,12,15)-OH(9)/16:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of hexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

PE(16:0/18:3(9,11,15)-OH(13))

C39H72NO9P (729.4944432)

PE(16:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(16:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one hexadecanoyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

PE(18:3(9,11,15)-OH(13)/16:0)

C39H72NO9P (729.4944432)

PE(18:3(9,11,15)-OH(13)/16:0) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(18:3(9,11,15)-OH(13)/16:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of hexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

PE(16:1(9Z)/18:1(12Z)-O(9S,10R))

C39H72NO9P (729.4944432)

PE(16:1(9Z)/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(16:1(9Z)/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one 9Z-hexadecenoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

PE(18:1(12Z)-O(9S,10R)/16:1(9Z))

C39H72NO9P (729.4944432)

PE(18:1(12Z)-O(9S,10R)/16:1(9Z)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(18:1(12Z)-O(9S,10R)/16:1(9Z)), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of 9Z-hexadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

PE(16:1(9Z)/18:1(9Z)-O(12,13))

C39H72NO9P (729.4944432)

PE(16:1(9Z)/18:1(9Z)-O(12,13)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(16:1(9Z)/18:1(9Z)-O(12,13)), in particular, consists of one chain of one 9Z-hexadecenoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

PE(18:1(9Z)-O(12,13)/16:1(9Z))

C39H72NO9P (729.4944432)

PE(18:1(9Z)-O(12,13)/16:1(9Z)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(18:1(9Z)-O(12,13)/16:1(9Z)), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of 9Z-hexadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

Ibrexafungerp 

C44H67N5O4 (729.5192781999999)

J - Antiinfectives for systemic use > J02 - Antimycotics for systemic use > J02A - Antimycotics for systemic use D000890 - Anti-Infective Agents > D000935 - Antifungal Agents C254 - Anti-Infective Agent > C514 - Antifungal Agent

Phosphatidylcholine 14:0-18:2

C40H76NO8P (729.5308266)

Phosphatidylcholine 16:1-16:1

C40H76NO8P (729.5308266)

Phosphatidylethanolamine 17:0-18:2

C40H76NO8P (729.5308266)

PE(16:1/13-HODE)

C39H72NO9P (729.4944432)

PE 35:2

C40H76NO8P (729.5308266)

Found in mouse small intestine; TwoDicalId=682; MgfFile=160907_Small_Intestine_EPA_Neg_08; MgfId=1314

C14H8Br6O5

C14H8Br6O5 (729.5471877999998)

PC 32:2

C40H76NO8P (729.5308266)

Found in mouse lung; TwoDicalId=192; MgfFile=160901_Lung_normal_Neg_03; MgfId=560 Found in mouse spleen; TwoDicalId=293; MgfFile=160729_spleen_EPA_06_Neg; MgfId=654 Found in mouse small intestine; TwoDicalId=863; MgfFile=160907_Small_Intestine_normal_Neg_01_2; MgfId=918

PC(14:0/18:2)

C40H76NO8P (729.5308266)

PC(14:0/18:2)[U]

C40H76NO8P (729.5308266)

PC(16:1/16:1)

C40H76NO8P (729.5308266)

PC(16:1/16:1)[U]

C40H76NO8P (729.5308266)

Dipalmitoleoyllecithin

C40H76NO8P (729.5308266)

Lecithin

C40H76NO8P (729.5308266)

PE(35:2)

C40H76NO8P (729.5308266)

PC(12:0/20:2(11Z,14Z))

C40H76NO8P (729.5308266)

PC(15:0/17:2(9Z,12Z))

C40H76NO8P (729.5308266)

PC(15:1(9Z)/17:1(9Z))

C40H76NO8P (729.5308266)

PC(17:1(9Z)/15:1(9Z))

C40H76NO8P (729.5308266)

PC(17:2(9Z,12Z)/15:0)

C40H76NO8P (729.5308266)

PC(20:2(11Z,14Z)/12:0)

C40H76NO8P (729.5308266)

PE(13:0/22:2(13Z,16Z))

C40H76NO8P (729.5308266)

PE(15:1(9Z)/20:1(11Z))

C40H76NO8P (729.5308266)

PE(16:1(9Z)/19:1(9Z))

C40H76NO8P (729.5308266)

PE(17:0/18:2(9Z,12Z))

C40H76NO8P (729.5308266)

PE(17:1(9Z)/18:1(9Z))

C40H76NO8P (729.5308266)

PE(17:2(9Z,12Z)/18:0)

C40H76NO8P (729.5308266)

PE(18:0/17:2(9Z,12Z))

C40H76NO8P (729.5308266)

PE(18:1(9Z)/17:1(9Z))

C40H76NO8P (729.5308266)

PE(18:2(9Z,12Z)/17:0)

C40H76NO8P (729.5308266)

PE(19:1(9Z)/16:1(9Z))

C40H76NO8P (729.5308266)

PE(20:1(11Z)/15:1(9Z))

C40H76NO8P (729.5308266)

PE(22:2(13Z,16Z)/13:0)

C40H76NO8P (729.5308266)

1-(6-[5]-ladderane-hexanyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerophosphoethanolamine

C43H72NO6P (729.5096982)

PS(P-16:0/17:2(9Z,12Z))

C39H72NO9P (729.4944432)

PE dO-38:9

C43H72NO6P (729.5096982)

PS O-33:3

C39H72NO9P (729.4944432)

Ibrexafungerp

C44H67N5O4 (729.5192781999999)

J - Antiinfectives for systemic use > J02 - Antimycotics for systemic use > J02A - Antimycotics for systemic use D000890 - Anti-Infective Agents > D000935 - Antifungal Agents C254 - Anti-Infective Agent > C514 - Antifungal Agent

[2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

2,3-bis[[(Z)-hexadec-9-enoyl]oxy]propyl 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptadecanoyloxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

C40H76NO8P (729.5308266)

1-myristoleoyl-2-vaccenoyl-sn-glycero-3-phosphocholine

C40H76NO8P (729.5308266)

PE(16:0/18:2(10E,12Z)+=O(9))

C39H72NO9P (729.4944432)

PE(18:2(10E,12Z)+=O(9)/16:0)

C39H72NO9P (729.4944432)

PE(16:0/18:2(9Z,11E)+=O(13))

C39H72NO9P (729.4944432)

PE(18:2(9Z,11E)+=O(13)/16:0)

C39H72NO9P (729.4944432)

PE(16:1(9Z)/18:1(12Z)-O(9S,10R))

C39H72NO9P (729.4944432)

PE(18:1(12Z)-O(9S,10R)/16:1(9Z))

C39H72NO9P (729.4944432)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate

C39H72NO9P (729.4944432)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-tetradecanoyloxypropyl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate

C39H72NO9P (729.4944432)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

C39H72NO9P (729.4944432)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hexadecanoyloxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

C39H72NO9P (729.4944432)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

C39H72NO9P (729.4944432)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hexadecanoyloxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

C39H72NO9P (729.4944432)

PE(16:1(9Z)/18:1(9Z)-O(12,13))

C39H72NO9P (729.4944432)

PE(18:1(9Z)-O(12,13)/16:1(9Z))

C39H72NO9P (729.4944432)

2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[8-[3-[(Z)-oct-2-enyl]oxiran-2-yl]octanoylamino]heptadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C40H78N2O7P+ (729.5546348)

2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]amino]heptadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C40H78N2O7P+ (729.5546348)

1-(10Z-heptadecenoyl)-2-oleoyl-sn-glycero-3-phosphoethanolamine zwitterion

C40H76NO8P (729.5308266)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-10-enoyl]oxypropan-2-yl] (Z)-octadec-9-enoate

C40H76NO8P (729.5308266)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoyl]oxypropan-2-yl] (Z)-octadec-9-enoate

C40H76NO8P (729.5308266)

[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-hexadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

Ldgcc 34:6

C44H75NO7 (729.554324)

HexCer 9:0;2O/28:7

C43H71NO8 (729.5179406)

HexCer 9:1;2O/28:6

C43H71NO8 (729.5179406)

HexCer 11:0;2O/26:7

C43H71NO8 (729.5179406)

HexCer 19:3;2O/18:4

C43H71NO8 (729.5179406)

HexCer 15:2;2O/22:5

C43H71NO8 (729.5179406)

HexCer 15:3;2O/22:4

C43H71NO8 (729.5179406)

HexCer 13:1;2O/24:6

C43H71NO8 (729.5179406)

HexCer 13:2;2O/24:5

C43H71NO8 (729.5179406)

HexCer 19:2;2O/18:5

C43H71NO8 (729.5179406)

HexCer 11:1;2O/26:6

C43H71NO8 (729.5179406)

HexCer 21:3;2O/16:4

C43H71NO8 (729.5179406)

HexCer 15:1;2O/22:6

C43H71NO8 (729.5179406)

HexCer 17:2;2O/20:5

C43H71NO8 (729.5179406)

HexCer 17:3;2O/20:4

C43H71NO8 (729.5179406)

Lnape 9:0/N-26:2

C40H76NO8P (729.5308266)

Lnape 26:2/N-9:0

C40H76NO8P (729.5308266)

2-[3-nonanoyloxy-2-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C43H71NO8 (729.5179406)

Lnape 15:1/N-20:1

C40H76NO8P (729.5308266)

Lnape 14:1/N-21:1

C40H76NO8P (729.5308266)

Lnape 22:2/N-13:0

C40H76NO8P (729.5308266)

Lnape 18:1/N-17:1

C40H76NO8P (729.5308266)

Lnape 14:0/N-21:2

C40H76NO8P (729.5308266)

Lnape 21:2/N-14:0

C40H76NO8P (729.5308266)

Lnape 20:1/N-15:1

C40H76NO8P (729.5308266)

Lnape 17:1/N-18:1

C40H76NO8P (729.5308266)

Lnape 11:0/N-24:2

C40H76NO8P (729.5308266)

Lnape 21:1/N-14:1

C40H76NO8P (729.5308266)

Lnape 16:1/N-19:1

C40H76NO8P (729.5308266)

Lnape 17:2/N-18:0

C40H76NO8P (729.5308266)

Lnape 18:2/N-17:0

C40H76NO8P (729.5308266)

Lnape 13:0/N-22:2

C40H76NO8P (729.5308266)

Lnape 19:1/N-16:1

C40H76NO8P (729.5308266)

Lnape 15:0/N-20:2

C40H76NO8P (729.5308266)

Lnape 13:1/N-22:1

C40H76NO8P (729.5308266)

Lnape 17:0/N-18:2

C40H76NO8P (729.5308266)

Lnape 16:2/N-19:0

C40H76NO8P (729.5308266)

Lnape 20:2/N-15:0

C40H76NO8P (729.5308266)

Lnape 19:2/N-16:0

C40H76NO8P (729.5308266)

Lnape 24:2/N-11:0

C40H76NO8P (729.5308266)

Lnape 19:0/N-16:2

C40H76NO8P (729.5308266)

Lnape 16:0/N-19:2

C40H76NO8P (729.5308266)

Lnape 22:1/N-13:1

C40H76NO8P (729.5308266)

Lnape 18:0/N-17:2

C40H76NO8P (729.5308266)

2-[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-undecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C43H71NO8 (729.5179406)

2-[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C43H71NO8 (729.5179406)

2-[3-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C43H71NO8 (729.5179406)

2-[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C43H71NO8 (729.5179406)

HexCer 8:0;3O/26:2;(2OH)

C40H75NO10 (729.539069)

HexCer 13:1;3O/21:1;(2OH)

C40H75NO10 (729.539069)

HexCer 12:0;3O/22:2;(2OH)

C40H75NO10 (729.539069)

HexCer 12:1;3O/22:1;(2OH)

C40H75NO10 (729.539069)

HexCer 10:0;3O/24:2;(2OH)

C40H75NO10 (729.539069)

(4E,8E)-2-[[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]amino]-3-hydroxydocosa-4,8-diene-1-sulfonic acid

C44H75NO5S (729.536566)

(4E,8E,12E)-2-[[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]amino]-3-hydroxydocosa-4,8,12-triene-1-sulfonic acid

C44H75NO5S (729.536566)

(4E,8E,12E)-3-hydroxy-2-[[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]amino]hexacosa-4,8,12-triene-1-sulfonic acid

C44H75NO5S (729.536566)

(4E,8E,12E)-2-[[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoyl]amino]-3-hydroxyoctadeca-4,8,12-triene-1-sulfonic acid

C44H75NO5S (729.536566)

(4E,8E,12E)-3-hydroxy-2-[[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]amino]tetracosa-4,8,12-triene-1-sulfonic acid

C44H75NO5S (729.536566)

(4E,8E)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]tetracosa-4,8-diene-1-sulfonic acid

C44H75NO5S (729.536566)

(E)-2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-3-hydroxydocos-4-ene-1-sulfonic acid

C44H75NO5S (729.536566)

(4E,8E)-3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]hexacosa-4,8-diene-1-sulfonic acid

C44H75NO5S (729.536566)

(E)-3-hydroxy-2-[[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoyl]amino]icos-4-ene-1-sulfonic acid

C44H75NO5S (729.536566)

(4E,8E,12E)-3-hydroxy-2-[[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]amino]icosa-4,8,12-triene-1-sulfonic acid

C44H75NO5S (729.536566)

2-[[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoyl]amino]-3-hydroxyoctadecane-1-sulfonic acid

C44H75NO5S (729.536566)

(E)-2-[[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoyl]amino]-3-hydroxyoctadec-4-ene-1-sulfonic acid

C44H75NO5S (729.536566)

(4E,8E)-3-hydroxy-2-[[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoyl]amino]icosa-4,8-diene-1-sulfonic acid

C44H75NO5S (729.536566)

(4E,8E)-2-[[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoyl]amino]-3-hydroxyoctadeca-4,8-diene-1-sulfonic acid

C44H75NO5S (729.536566)

2-amino-3-[hydroxy-[2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxy-3-[(Z)-tetradec-9-enoxy]propoxy]phosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

2-amino-3-[[2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxy-3-undecoxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

2-amino-3-[hydroxy-[3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]-2-tridecanoyloxypropoxy]phosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

2-amino-3-[[3-heptadecoxy-2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

2-amino-3-[hydroxy-[3-[(9Z,12Z)-octadeca-9,12-dienoxy]-2-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

2-amino-3-[[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-[(Z)-hexadec-9-enoxy]propoxy]-hydroxyphosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

2-amino-3-[hydroxy-[3-[(11Z,14Z)-icosa-11,14-dienoxy]-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

2-amino-3-[[2-heptadecanoyloxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propoxy]-hydroxyphosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

2-amino-3-[[3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoxy]-2-undecanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

2-amino-3-[hydroxy-[3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]-2-pentadecanoyloxypropoxy]phosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

2-amino-3-[hydroxy-[2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxy-3-tridecoxypropoxy]phosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

2-amino-3-[hydroxy-[2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-[(Z)-tridec-9-enoxy]propoxy]phosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

2-amino-3-[[3-[(9Z,12Z)-heptadeca-9,12-dienoxy]-2-[(Z)-hexadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

2-amino-3-[[3-[(Z)-heptadec-9-enoxy]-2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

2-amino-3-[hydroxy-[2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxy-3-pentadecoxypropoxy]phosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

2-amino-3-[hydroxy-[2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-[(Z)-pentadec-9-enoxy]propoxy]phosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

2-amino-3-[hydroxy-[3-[(9Z,12Z)-nonadeca-9,12-dienoxy]-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

2-amino-3-[[2-[(Z)-heptadec-9-enoyl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propoxy]-hydroxyphosphoryl]oxypropanoic acid

C39H72NO9P (729.4944432)

OxPE 34:3+1O

C39H72NO9P (729.4944432)

4-[2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-dodecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[3-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[3-[(Z)-hexadec-9-enoyl]oxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[3-hexadecanoyloxy-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

HexCer 22:2;3O/12:0;(2OH)

C40H75NO10 (729.539069)

HexCer 21:1;3O/13:1;(2OH)

C40H75NO10 (729.539069)

HexCer 16:0;3O/18:2;(2OH)

C40H75NO10 (729.539069)

HexCer 19:1;3O/15:1;(2OH)

C40H75NO10 (729.539069)

HexCer 18:2;3O/16:0;(2OH)

C40H75NO10 (729.539069)

HexCer 15:2;3O/19:0;(2OH)

C40H75NO10 (729.539069)

HexCer 22:1;3O/12:1;(2OH)

C40H75NO10 (729.539069)

HexCer 17:2;3O/17:0;(2OH)

C40H75NO10 (729.539069)

HexCer 18:1;3O/16:1;(2OH)

C40H75NO10 (729.539069)

HexCer 16:1;3O/18:1;(2OH)

C40H75NO10 (729.539069)

HexCer 15:1;3O/19:1;(2OH)

C40H75NO10 (729.539069)

HexCer 14:2;3O/20:0;(2OH)

C40H75NO10 (729.539069)

HexCer 16:2;3O/18:0;(2OH)

C40H75NO10 (729.539069)

HexCer 14:0;3O/20:2;(2OH)

C40H75NO10 (729.539069)

HexCer 19:2;3O/15:0;(2OH)

C40H75NO10 (729.539069)

HexCer 21:2;3O/13:0;(2OH)

C40H75NO10 (729.539069)

HexCer 18:0;3O/16:2;(2OH)

C40H75NO10 (729.539069)

HexCer 14:1;3O/20:1;(2OH)

C40H75NO10 (729.539069)

HexCer 20:1;3O/14:1;(2OH)

C40H75NO10 (729.539069)

HexCer 20:2;3O/14:0;(2OH)

C40H75NO10 (729.539069)

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxypropyl] nonadecanoate

C40H76NO8P (729.5308266)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate

C40H76NO8P (729.5308266)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate

C40H76NO8P (729.5308266)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (Z)-henicos-11-enoate

C40H76NO8P (729.5308266)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (Z)-docos-13-enoate

C40H76NO8P (729.5308266)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropan-2-yl] (Z)-icos-11-enoate

C40H76NO8P (729.5308266)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-undecanoyloxypropan-2-yl] (13Z,16Z)-tetracosa-13,16-dienoate

C40H76NO8P (729.5308266)

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxypropyl] octadecanoate

C40H76NO8P (729.5308266)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (13Z,16Z)-docosa-13,16-dienoate

C40H76NO8P (729.5308266)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoyl]oxypropan-2-yl] (Z)-nonadec-9-enoate

C40H76NO8P (729.5308266)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

C40H76NO8P (729.5308266)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptadecanoyloxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate

C40H76NO8P (729.5308266)

[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-pentadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[3-decanoyloxy-2-[(13Z,16Z)-docosa-13,16-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[3-dodecanoyloxy-2-[(11Z,14Z)-icosa-11,14-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] (15Z,18Z)-hexacosa-15,18-dienoate

C40H76NO8P (729.5308266)

[2-[(Z)-octadec-9-enoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[2-[(Z)-nonadec-9-enoyl]oxy-3-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[2-[(15Z,18Z)-hexacosa-15,18-dienoyl]oxy-3-hexanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxy-3-tridecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[2-[(Z)-heptadec-9-enoyl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[2-[(11Z,14Z)-henicosa-11,14-dienoyl]oxy-3-undecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[3-octanoyloxy-2-[(13Z,16Z)-tetracosa-13,16-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[(2S)-2-dodecanoyloxy-3-[(11E,14E)-icosa-11,14-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[3-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxy-2-pentadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[3-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxy-2-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-pentadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(10E,12E)-octadeca-10,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (5E,8E)-icosa-5,8-dienoate

C40H76NO8P (729.5308266)

4-[2-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-dodecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[2-[(11E,14E)-heptadeca-11,14-dienoyl]oxy-3-[(8E,11E,14E)-heptadeca-8,11,14-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[3-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-2-[(10E,12E)-octadeca-10,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[2-[(10E,13E,16E)-nonadeca-10,13,16-trienoyl]oxy-3-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-heptadec-9-enoyl]oxypropan-2-yl] octadec-17-enoate

C40H76NO8P (729.5308266)

[(2R)-2-[(E)-octadec-6-enoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[3-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(E)-heptadec-9-enoyl]oxypropyl] octadec-17-enoate

C40H76NO8P (729.5308266)

[(2R)-2-[(9E,11E)-octadeca-9,11-dienoyl]oxy-3-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[2-[(E)-dec-4-enoyl]oxy-3-[(9E,12E,15E,18E)-tetracosa-9,12,15,18-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-2-[(6E,9E)-octadeca-6,9-dienoyl]oxy-3-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[2-[(E)-hexadec-7-enoyl]oxy-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-3-[(9E,11E)-octadeca-9,11-dienoyl]oxy-2-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-2-octadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[2-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[(15E,18E,21E)-tetracosa-15,18,21-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-3-[(E)-octadec-13-enoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(E)-heptadec-9-enoyl]oxypropyl] (E)-octadec-13-enoate

C40H76NO8P (729.5308266)

4-[2-decanoyloxy-3-[(6E,9E,12E,15E,18E)-tetracosa-6,9,12,15,18-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-heptadec-9-enoyl]oxypropan-2-yl] (E)-octadec-13-enoate

C40H76NO8P (729.5308266)

[(2R)-3-[(E)-octadec-6-enoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (11E,14E)-icosa-11,14-dienoate

C40H76NO8P (729.5308266)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(E)-heptadec-9-enoyl]oxypropyl] (E)-octadec-4-enoate

C40H76NO8P (729.5308266)

4-[2-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2S)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(E)-pentadec-9-enoyl]oxypropyl] (E)-icos-13-enoate

C40H76NO8P (729.5308266)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(E)-heptadec-9-enoyl]oxypropyl] (E)-octadec-6-enoate

C40H76NO8P (729.5308266)

4-[3-[(11E,14E)-heptadeca-11,14-dienoyl]oxy-2-[(8E,11E,14E)-heptadeca-8,11,14-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(4E,7E)-hexadeca-4,7-dienoyl]oxypropyl] nonadecanoate

C40H76NO8P (729.5308266)

[(2R)-3-[(E)-hexadec-7-enoyl]oxy-2-[(E)-hexadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[(2R)-3-[(E)-octadec-4-enoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-heptadecanoyloxypropyl] (9E,11E)-octadeca-9,11-dienoate

C40H76NO8P (729.5308266)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9E,12E)-heptadeca-9,12-dienoyl]oxypropan-2-yl] octadecanoate

C40H76NO8P (729.5308266)

[(2R)-3-decanoyloxy-2-[(13E,16E)-docosa-13,16-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[2-[(9E,11E,13E,15E)-henicosa-9,11,13,15-tetraenoyl]oxy-3-[(E)-tridec-8-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(E)-heptadec-9-enoyl]oxypropyl] (E)-octadec-11-enoate

C40H76NO8P (729.5308266)

[(2R)-3-dodecanoyloxy-2-[(11E,14E)-icosa-11,14-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[(2R)-3-[(E)-heptadec-9-enoyl]oxy-2-[(E)-pentadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[2-[(11E,14E,17E,20E)-tricosa-11,14,17,20-tetraenoyl]oxy-3-[(E)-undec-4-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-3-[(9E,12E)-octadeca-9,12-dienoyl]oxy-2-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[2-[(14E,16E)-docosa-14,16-dienoyl]oxy-3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-2-[(9E,12E)-octadeca-9,12-dienoyl]oxy-3-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[(2S)-2-dodecanoyloxy-3-[(5E,8E)-icosa-5,8-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-heptadec-9-enoyl]oxypropan-2-yl] (E)-octadec-11-enoate

C40H76NO8P (729.5308266)

[(2R)-2-octadec-17-enoyloxy-3-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[(2R)-2-[(E)-octadec-9-enoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[3-[(13E,16E,19E)-docosa-13,16,19-trienoyl]oxy-2-[(6E,9E)-dodeca-6,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-heptadecanoyloxypropyl] (9E,12E)-octadeca-9,12-dienoate

C40H76NO8P (729.5308266)

4-[3-[(11E,14E)-icosa-11,14-dienoyl]oxy-2-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-3-[(E)-octadec-11-enoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-heptadecanoyloxypropyl] (6E,9E)-octadeca-6,9-dienoate

C40H76NO8P (729.5308266)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptadecanoyloxypropan-2-yl] (2E,4E)-octadeca-2,4-dienoate

C40H76NO8P (729.5308266)

4-[3-[(9E,11E,13E,15E,17E)-henicosa-9,11,13,15,17-pentaenoyl]oxy-2-tridecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptadecanoyloxypropan-2-yl] (6E,9E)-octadeca-6,9-dienoate

C40H76NO8P (729.5308266)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-heptadec-9-enoyl]oxypropan-2-yl] (E)-octadec-9-enoate

C40H76NO8P (729.5308266)

4-[3-[(E)-hexadec-7-enoyl]oxy-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[3-decanoyloxy-2-[(6E,9E,12E,15E,18E)-tetracosa-6,9,12,15,18-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[3-[(7E,9E)-nonadeca-7,9-dienoyl]oxy-2-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[3-[(4E,7E)-deca-4,7-dienoyl]oxy-2-[(15E,18E,21E)-tetracosa-15,18,21-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2S)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-tridecanoyloxypropyl] (13E,16E)-docosa-13,16-dienoate

C40H76NO8P (729.5308266)

[(2R)-2,3-bis[[(E)-hexadec-7-enoyl]oxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[2-[(7E,9E)-nonadeca-7,9-dienoyl]oxy-3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-2-[(2E,4E)-octadeca-2,4-dienoyl]oxy-3-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[3-[(9E,11E,13E,15E)-henicosa-9,11,13,15-tetraenoyl]oxy-2-[(E)-tridec-8-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-pentadec-9-enoyl]oxypropan-2-yl] (E)-icos-11-enoate

C40H76NO8P (729.5308266)

4-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-octadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-heptadecanoyloxypropyl] (2E,4E)-octadeca-2,4-dienoate

C40H76NO8P (729.5308266)

[(2R)-3-dodecanoyloxy-2-[(5E,8E)-icosa-5,8-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[2-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxy-3-pentadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2S)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-pentadecanoyloxypropyl] (11E,14E)-icosa-11,14-dienoate

C40H76NO8P (729.5308266)

4-[2-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(E)-heptadec-9-enoyl]oxypropyl] (E)-octadec-9-enoate

C40H76NO8P (729.5308266)

4-[3-[(10E,13E,16E,19E)-docosa-10,13,16,19-tetraenoyl]oxy-2-[(E)-dodec-5-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[3-[(8E,11E,14E,17E,20E)-tricosa-8,11,14,17,20-pentaenoyl]oxy-2-undecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2S)-2-decanoyloxy-3-[(13E,16E)-docosa-13,16-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[2-[(7E,10E,13E,16E)-nonadeca-7,10,13,16-tetraenoyl]oxy-3-[(E)-pentadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-3-octadec-17-enoyloxy-2-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[2-hexadecanoyloxy-3-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptadecanoyloxypropan-2-yl] (9E,11E)-octadeca-9,11-dienoate

C40H76NO8P (729.5308266)

4-[2-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-2-[(E)-octadec-11-enoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[(2R)-2-[(E)-octadec-7-enoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[3-hexadecanoyloxy-2-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-hexadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[3-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxy-2-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-2-[(E)-octadec-13-enoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[(2R)-3-[(2E,4E)-octadeca-2,4-dienoyl]oxy-2-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[2-[(11E,14E)-icosa-11,14-dienoyl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[3-[(7E,10E,13E,16E)-nonadeca-7,10,13,16-tetraenoyl]oxy-2-[(E)-pentadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[2-[(10E,13E,16E,19E)-docosa-10,13,16,19-tetraenoyl]oxy-3-[(E)-dodec-5-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-2-[(E)-octadec-4-enoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[2-[(9E,11E,13E,15E,17E)-henicosa-9,11,13,15,17-pentaenoyl]oxy-3-tridecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(E)-octadec-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[3-[(E)-dec-4-enoyl]oxy-2-[(9E,12E,15E,18E)-tetracosa-9,12,15,18-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxypropyl] octadecanoate

C40H76NO8P (729.5308266)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (13E,16E)-docosa-13,16-dienoate

C40H76NO8P (729.5308266)

[(2S)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(E)-pentadec-9-enoyl]oxypropyl] (E)-icos-11-enoate

C40H76NO8P (729.5308266)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(E)-heptadec-9-enoyl]oxypropyl] (E)-octadec-7-enoate

C40H76NO8P (729.5308266)

[(2R)-3-[(6E,9E)-octadeca-6,9-dienoyl]oxy-2-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-heptadec-9-enoyl]oxypropan-2-yl] (E)-octadec-6-enoate

C40H76NO8P (729.5308266)

[(2R)-3-[(E)-octadec-9-enoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[3-[(14E,16E)-docosa-14,16-dienoyl]oxy-2-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[2-[(13E,16E,19E)-docosa-13,16,19-trienoyl]oxy-3-[(6E,9E)-dodeca-6,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-pentadec-9-enoyl]oxypropan-2-yl] (E)-icos-13-enoate

C40H76NO8P (729.5308266)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-heptadec-9-enoyl]oxypropan-2-yl] (E)-octadec-7-enoate

C40H76NO8P (729.5308266)

[(2R)-2-[(E)-heptadec-9-enoyl]oxy-3-[(E)-pentadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

[(2S)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-pentadecanoyloxypropyl] (5E,8E)-icosa-5,8-dienoate

C40H76NO8P (729.5308266)

[(2R)-2-[(E)-hexadec-7-enoyl]oxy-3-[(E)-hexadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[3-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-2-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[2-[(8E,11E,14E,17E,20E)-tricosa-8,11,14,17,20-pentaenoyl]oxy-3-undecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[3-[(10E,13E,16E)-nonadeca-10,13,16-trienoyl]oxy-2-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-2-[(E)-octadec-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-3-[(E)-octadec-7-enoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

4-[3-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxy-2-dodecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

4-[3-[(11E,14E,17E,20E)-tricosa-11,14,17,20-tetraenoyl]oxy-2-[(E)-undec-4-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H75NO7 (729.554324)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-heptadec-9-enoyl]oxypropan-2-yl] (E)-octadec-4-enoate

C40H76NO8P (729.5308266)

[(2R)-3-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-2-pentadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H76NO8P (729.5308266)

2-[[(8E,12E)-2-[[(Z)-heptadec-9-enoyl]amino]-3,4-dihydroxyoctadeca-8,12-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C40H78N2O7P+ (729.5546348)

2-[[(4E,8E,12E)-2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-3-hydroxypentadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C42H70N2O6P+ (729.4971230000001)

2-[[(8E,12E,16E)-2-(heptadecanoylamino)-3,4-dihydroxyoctadeca-8,12,16-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C40H78N2O7P+ (729.5546348)

2-[[(E)-2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3,4-dihydroxyoctadec-8-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C40H78N2O7P+ (729.5546348)

1,2-Dipalmitoleoyl-sn-glycero-3-phosphocholine

C40H76NO8P (729.5308266)

A phosphatidylcholine 32:2 in which both phosphatidyl acyl groups are specified as palmitoleoyl.

1-tetradecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine

C40H76NO8P (729.5308266)

1-(9Z,12Z-octadecadienoyl)-2-tetradecanoyl-glycero-3-phosphocholine

C40H76NO8P (729.5308266)

1-(9Z-tetradecenoyl)-2-(9Z-octadecenoyl)-glycero-3-phosphocholine

C40H76NO8P (729.5308266)

1-(9Z-octadecenoyl)-2-(9Z-tetradecenoyl)-glycero-3-phosphocholine

C40H76NO8P (729.5308266)

1-Vaccenoyl-2-myristoleoyl-sn-glycero-3-phosphocholine

C40H76NO8P (729.5308266)

1-pentadecanoyl-2-(11Z,14Z-eicosadienoyl)-glycero-3-phosphoethanolamine

C40H76NO8P (729.5308266)

1-(11Z,14Z-eicosadienoyl)-2-pentadecanoyl-glycero-3-phosphoethanolamine

C40H76NO8P (729.5308266)

PE-NMe(16:1(9Z)/18:1(9Z))

C40H76NO8P (729.5308266)

PE-NMe(16:0/18:2(9Z,12Z))

C40H76NO8P (729.5308266)

PE-NMe(18:1(9Z)/16:1(9Z))

C40H76NO8P (729.5308266)

PE-NMe(18:2(9Z,12Z)/16:0)

C40H76NO8P (729.5308266)

PE-NMe(14:1(9Z)/20:1(11Z))

C40H76NO8P (729.5308266)

PE-NMe(16:1(9Z)/18:1(11Z))

C40H76NO8P (729.5308266)

PE-NMe(14:0/20:2(11Z,14Z))

C40H76NO8P (729.5308266)

PE-NMe(18:1(11Z)/16:1(9Z))

C40H76NO8P (729.5308266)

PE-NMe(20:1(11Z)/14:1(9Z))

C40H76NO8P (729.5308266)

PE-NMe(20:2(11Z,14Z)/14:0)

C40H76NO8P (729.5308266)

PE-NMe2(15:0/18:2(9Z,12Z))

C40H76NO8P (729.5308266)

PE-NMe2(18:2(9Z,12Z)/15:0)

C40H76NO8P (729.5308266)

1,2-di-(9E-hexadecenoyl)-sn-glycero-3-phosphocholine

C40H76NO8P (729.5308266)

A phosphatidylcholine 32:2 in which the acyl group at both positions 1 and 2 is (9E)-hexadecenoyl respectively.

1-(9Z-heptadecenoyl)-2-(9Z-octadecenoyl)-glycero-3-phosphoethanolamine

C40H76NO8P (729.5308266)

1-tetradecanoyl-2-(11Z,14Z-octadecadienoyl)-sn-glycero-3-phosphocholine

C40H76NO8P (729.5308266)

1-dodecanoyl-2-(11Z,14Z-eicosadienoyl)-glycero-3-phosphocholine

C40H76NO8P (729.5308266)

1-heptadecanoyl-2-(9Z,12Z-octadecadienoyl)-glycero-3-phosphoethanolamine

C40H76NO8P (729.5308266)

1-(9Z-octadecenoyl)-2-(9Z-heptadecenoyl)-glycero-3-phosphoethanolamine

C40H76NO8P (729.5308266)

1-tridecanoyl-2-(13Z,16Z-docosadienoyl)-glycero-3-phosphoethanolamine

C40H76NO8P (729.5308266)

1-(9Z-pentadecenoyl)-2-(9Z-heptadecenoyl)-glycero-3-phosphocholine

C40H76NO8P (729.5308266)

1-pentadecanoyl-2-(9Z,12Z-heptadecadienoyl)-glycero-3-phosphocholine

C40H76NO8P (729.5308266)

1-(9Z,12Z-heptadecadienoyl)-2-pentadecanoyl-glycero-3-phosphocholine

C40H76NO8P (729.5308266)

1-(11Z,14Z-eicosadienoyl)-2-dodecanoyl-glycero-3-phosphocholine

C40H76NO8P (729.5308266)

1-octadecanoyl-2-(9Z,12Z-heptadecadienoyl)-glycero-3-phosphoethanolamine

C40H76NO8P (729.5308266)

1-(9Z-nonadecenoyl)-2-(9Z-hexadecenoyl)-glycero-3-phosphoethanolamine

C40H76NO8P (729.5308266)

1-(9Z-heptadecenoyl)-2-(9Z-pentadecenoyl)-glycero-3-phosphocholine

C40H76NO8P (729.5308266)

1-(9Z-hexadecenoyl)-2-(9Z-nonadecenoyl)-glycero-3-phosphoethanolamine

C40H76NO8P (729.5308266)

1-(9Z,12Z-heptadecadienoyl)-2-octadecanoyl-glycero-3-phosphoethanolamine

C40H76NO8P (729.5308266)

1-(9Z,12Z-octadecadienoyl)-2-heptadecanoyl-glycero-3-phosphoethanolamine

C40H76NO8P (729.5308266)

1-(9Z-pentadecenoyl)-2-(11Z-eicosenoyl)-glycero-3-phosphoethanolamine

C40H76NO8P (729.5308266)

1-(13Z,16Z-docosadienoyl)-2-tridecanoyl-glycero-3-phosphoethanolamine

C40H76NO8P (729.5308266)

1-(11Z-eicosenoyl)-2-(9Z-pentadecenoyl)-glycero-3-phosphoethanolamine

C40H76NO8P (729.5308266)

phosphatidylcholine 32:2

C40H76NO8P (729.5308266)

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 32 carbons in total with 2 double bonds.

phosphatidylethanolamine (17:1/18:1)

C40H76NO8P (729.5308266)

A phosphatidylethanolamine 35:2 in which the acyl group at C-1 contains 17 carbons and 1 double bond while that at C-2 contains 18 carbons and 1 double bond.

phosphatidylcholine (14:0/18:2)

C40H76NO8P (729.5308266)

A phosphatidylcholine 32:2 in which the fatty acyl groups at positions 1 and 2 are specified as C14:0 and C18:2 respectively.

phosphatidylcholine (16:1/16:1)

C40H76NO8P (729.5308266)

A phosphatidylcholine 32:2 in which both the fatty acyl groups at positions 1 and 2 are specified as C16:1.

phosphatidylcholine (16:2/16:0)

C40H76NO8P (729.5308266)

A phosphatidylcholine 32:2 in which the fatty acyl groups at positions 1 and 2 are specified as C16:2 and C16:0 respectively.

1-tetradecanoyl-2-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine

C40H76NO8P (729.5308266)

A phosphatidylcholine 32:2 in which the acyl groups specified at positions 1 and 2 are tetradecanoyl and (9Z,12Z)-octadecadienoyl respectively.

MePC(31:2)

C40H76NO8P (729.5308266)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

CerP(43:8)

C43H72NO6P (729.5096982)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

CerP(40:3)

C40H76NO8P (729.5308266)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

CerP(44:7)

C44H76NO5P (729.5460815999999)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

Hex1Cer(37:7)

C43H71NO8 (729.5179406)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

dMePE(33:2)

C40H76NO8P (729.5308266)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

Hex1Cer(34:2)

C40H75NO10 (729.539069)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

DGCC 30:1;O2

C40H75NO10 (729.539069)

DGCC 33:6

C43H71NO8 (729.5179406)

DGTS 33:6;O

C43H71NO8 (729.5179406)

DGTS 34:5

C44H75NO7 (729.554324)

MGCC 34:6

C44H75NO7 (729.554324)

PC O-18:0/13:4;O2

C39H72NO9P (729.4944432)

PC O-20:0/12:3;O

C40H76NO8P (729.5308266)

PC O-31:4;O2

C39H72NO9P (729.4944432)

PC O-32:3;O

C40H76NO8P (729.5308266)

PC P-18:0/13:3;O2

C39H72NO9P (729.4944432)

PC 18:0/13:3;O

C39H72NO9P (729.4944432)

PC 20:1/11:2;O

C39H72NO9P (729.4944432)

PC 22:2/9:1;O

C39H72NO9P (729.4944432)

PC 31:3;O

C39H72NO9P (729.4944432)

PC 10:0_22:2

C40H76NO8P (729.5308266)

PC 12:0_20:2

C40H76NO8P (729.5308266)

PC 14:0_18:2

C40H76NO8P (729.5308266)

PC 14:0/18:2

C40H76NO8P (729.5308266)

PC 14:1_18:1

C40H76NO8P (729.5308266)

PC 15:0_17:2

C40H76NO8P (729.5308266)

PC 15:1_17:1

C40H76NO8P (729.5308266)

PC 16:0_16:2

C40H76NO8P (729.5308266)

PC 16:1/16:1

C40H76NO8P (729.5308266)

PC 16:1(7Z)/16:1(7Z)

C40H76NO8P (729.5308266)

PC 18:1/14:1

C40H76NO8P (729.5308266)

LNAPE 34:3;O

C39H72NO9P (729.4944432)

LNAPE 35:2

C40H76NO8P (729.5308266)

PE O-34:4;O2

C39H72NO9P (729.4944432)

PE P-16:1/18:2;O2

C39H72NO9P (729.4944432)

PE 14:0/20:3;O

C39H72NO9P (729.4944432)

PE 14:1/20:2;O

C39H72NO9P (729.4944432)

PE 16:0/18:3;O

C39H72NO9P (729.4944432)

PE 16:1/18:2;O

C39H72NO9P (729.4944432)

PE 22:0/12:3;O

C39H72NO9P (729.4944432)

PE 34:3;O

C39H72NO9P (729.4944432)

PE 13:0_22:2

C40H76NO8P (729.5308266)

PE 15:0_20:2

C40H76NO8P (729.5308266)

PE 15:0/20:2

C40H76NO8P (729.5308266)

PE 15:1_20:1

C40H76NO8P (729.5308266)

PE 17:0_18:2

C40H76NO8P (729.5308266)

PE 17:0/18:2

C40H76NO8P (729.5308266)

PE 17:1_18:1

C40H76NO8P (729.5308266)

PE 17:2_18:0

C40H76NO8P (729.5308266)

PE-NMe 16:0_18:2

C40H76NO8P (729.5308266)

PS O-16:1/17:2

C39H72NO9P (729.4944432)

PS O-16:2/17:1

C39H72NO9P (729.4944432)

PS O-18:2/15:1

C39H72NO9P (729.4944432)

PS P-16:0/17:2

C39H72NO9P (729.4944432)

PS P-16:0/17:2 or PS O-16:1/17:2

C39H72NO9P (729.4944432)

PS P-16:1/17:1

C39H72NO9P (729.4944432)

PS P-16:1/17:1 or PS O-16:2/17:1

C39H72NO9P (729.4944432)

PS P-18:1/15:1

C39H72NO9P (729.4944432)

PS P-18:1/15:1 or PS O-18:2/15:1

C39H72NO9P (729.4944432)

PS P-33:2

C39H72NO9P (729.4944432)

PS P-33:2 or PS O-33:3

C39H72NO9P (729.4944432)

CerP 21:2;O2/22:6

C43H72NO6P (729.5096982)

CerP 43:8;O2

C43H72NO6P (729.5096982)

GalCer 15:1;O2/22:6

C43H71NO8 (729.5179406)

GalCer 15:2;O2/22:5

C43H71NO8 (729.5179406)

GalCer 17:2;O2/20:5

C43H71NO8 (729.5179406)

GalCer 37:7;O2

C43H71NO8 (729.5179406)

GlcCer 15:1;O2/22:6

C43H71NO8 (729.5179406)

GlcCer 15:2;O2/22:5

C43H71NO8 (729.5179406)

GlcCer 17:2;O2/20:5

C43H71NO8 (729.5179406)

GlcCer 37:7;O2

C43H71NO8 (729.5179406)

HexCer 15:1;O2/22:6

C43H71NO8 (729.5179406)

HexCer 15:2;O2/22:5

C43H71NO8 (729.5179406)

HexCer 17:2;O2/20:5

C43H71NO8 (729.5179406)

HexCer 34:2;O4

C40H75NO10 (729.539069)

HexCer 37:7;O2

C43H71NO8 (729.5179406)

GLCAE 21:6

C47H71NO5 (729.5331955999999)

TLCAE 17:3

C43H71NO6S (729.5001826)

3,4,6-tribromo-5-{[(2,3,6-tribromo-4,5-dihydroxyphenyl)methoxy]methyl}benzene-1,2-diol

C14H8Br6O5 (729.5471877999998)